IL1B and cervical squamous cell carcinoma: Furthermore, based on primary therapy outcome, the expression levels of IL1A, IL1B, and TICAM2 were significantly higher in progressive disease (PD) patients with CESC than those in the stable disease (SD), partial response (PR), and complete response (CR) patients (P < 0.05; Tables 4, 5, and 7).